New agents and techniques for imaging prostate cancer

Journal of Nuclear Medicine

Volumn 50, Issue 9, 2009, Pages 1387-1390

  Zaheer, Atif ^a   Cho, Steve Y ^a   Pomper, Martin G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Molecular imaging; MRI; PET; Radiopharmaceutical; SPECT

Indexed keywords

CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; HUMAN; INTERVENTION STUDY; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; IMAGE ENHANCEMENT; MALE; MOLECULAR PROBE TECHNIQUES; NUCLEAR MEDICINE; PROSTATIC NEOPLASMS; RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 69449089271     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.061838     Document Type: Review

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
3. Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.Nature. 2009;457:910-914.
4. Kelloff GJ. Issues in clinical prostate cancer: role of imaging. AJR. 2009;192:1455-1470.
5. Bak JB, Landas SK, Haas GP. Characterization of prostate cancer missed by sextant biopsy. Clin Prostate Cancer. 2003;2:115-118. (Pubitemid 37296106)
6. Futterer JJ, Engelbrecht MR, Jager GJ, et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils-local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol. 2007;17:1055-1065.
7. Mueller-Lisse UG, Scherr MK. Proton MR spectroscopy of the prostate. Eur J Radiol. 2007;63:351-360.
8. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000;164:400-404. (Pubitemid 30481935)
9. Costouros NG, Coakley FV, Westphalen AC, et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR. 2007;188:812-816.
10. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804-814. (Pubitemid 40250824)
11. Klomp DW, Bitz AK, Heerschap A, Scheenen TW. Proton spectroscopic imaging of the human prostate at 7 T. NMR Biomed. 2009;22:495-501.
12. Singh AK, Kruecker J, Xu S, et al. Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. BJU Int. 2008;101:841-845. (Pubitemid 351347719)
13. Bax J, Cool D, Gardi L, et al. Mechanically assisted 3D ultrasound guided prostate biopsy system. Med Phys. 2008;35:5397-5410.
14. 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res. 2008;68:8607-8615.
15. 11C-choline PET/CT. Radiology. 2007;244:797-806.
16. 11C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy. Eur J Nucl Med Mol Imaging. 2008;35:1065-1073.
17. 18F-fluorocholine PET sextant localization of prostate cancer. Mol Imaging. 2008;7:12-20.
18. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-186.
19. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
20. Bloch BN, Furman-Haran E, Helbich TH, et al. Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging: initial results. Radiology. 2007;245:176-185. (Pubitemid 47417801)
21. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499. (Pubitemid 36706536)
22. van As NJ, de Souza NM, Riches SF, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol. December 6, 2008 [Epub ahead of print].
23. Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: present and future. Curr Opin Urol. 2008;18:71-77. (Pubitemid 350307535)
24. Tamada T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging. 2008;28:720-726.
25. Xu J, Humphrey PA, Kibel AS, et al. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med. 2009;61:842-850.
26. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am. 1993;20:713-725.
27. 11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52:423-429.
28. 18F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:253-263.
29. 11C-acetate PET imaging in prostate cancer. Eur J Nucl Med Mol Imaging. 2007;34:181-184.
30. Nargund V, Al Hashmi D, Kumar P, et al. Imaging with radiolabelled monoclonal antibody (MUJ591) to prostate-specific membrane antigen in staging of clinically localized prostatic carcinoma: comparison with clinical, surgical and histological staging. BJU Int. 2005;95:1232-1236. (Pubitemid 40799436)
31. Elsasser-Beile U, Reischl G, Wiehr S, et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med. 2009;50:606-611.
32. 18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
33. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517.
34. 99mTc-radioimaging agents. Mol Pharm. 2009;6:790-800.
35. 123I- MIP1095 [abstract]. J Nucl Med. 2009;50(suppl):136P.
36. 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47:287-297.
37. 18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005;32:15-22.
38. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344-350. (Pubitemid 40562127)
39. Barton KN, Stricker H, Brown SL, et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther. 2008;16:1761-1769.
40. Zhang K, Aruva MR, Shanthly N, et al. PET imaging of VPAC1 expression in experimental and spontaneous prostate cancer. J Nucl Med. 2008;49:112-121.